Menu
Recruiting NCT07309107

Deep Learning on Amyloid Positons Emission Tomography

— Observational Alzheimer Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Alzheimer Disease. Basic parameters: 18 years — 99 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Impact of Deep Learning-Based Noise Reduction Algorithm on Visual Analysis and Centiloid Quantification in Reduced-Dose and, or Time Acquisition Amyloid PET Imaging

Overview

Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of \[18F\]flutemetamol.

Primary outcome measures

  • Evaluate the impact of a deep-learning noise reduction algorithm on visual analysis and centiloid quantification when simulating reduced injected doses of 18F-flutemetamol. [Time frame: Day one]

Eligibility criteria

Inclusion criteria

  • Patients with objective cognitive impairment,
  • Referred to our department for a cerebral \[¹⁸F\]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,

Exclusion criteria

  • Patient have objected to the use of their data.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Other

Study locations

France · 3 centers
  • CHRU NANCY Brabois, nuclear medicine department — Vandœuvre-lès-Nancy
  • Nancy's hospital — Vandœuvre-lès-Nancy
  • Nuclear medicine department CHRU de NANCY Brabois — Vandœuvre-lès-Nancy

Identifiers

NCT: NCT07309107 · 2025PI190

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗